CREBBP and B-cell non-Hodgkin lymphoma: We subjected the 697 isogenic cell lines to a targeted drug screen, using a wide range of concentrations, focussed on clinically-actionable drugs in classes implicated or hypothesized to show differential sensitivity in published models of B-cell lymphoma and other CREBBP-mutated malignancies (Supplementary Data Table 1)3,4,10–12,18,20,22.